Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating gout and application thereof

A composition and medicine technology, applied in the field of medicine, can solve the problem of high incidence of gout, and achieve the effects of promoting uric acid excretion and broad application prospects

Inactive Publication Date: 2012-10-03
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The etiology is mainly caused by two factors, congenital genes and acquired dietary environment. If there is no genetic gout constitution, it is not easy to cause gout due to overeating, but if it is a constitution with high uric acid, the incidence of gout is less likely. high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating gout and application thereof
  • Pharmaceutical composition for treating gout and application thereof
  • Pharmaceutical composition for treating gout and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] The preparation of embodiment 1 apigenin A, apigenin B, neocnidolide one

[0026] 1 material

[0027] Celery seed; column chromatography filler: silica gel (100-200 mesh, 200-300 mesh), purchased from Zhifu Silica Gel Development and Experimental Factory in Yantai, Shandong; ethanol, ethyl acetate (EtOAc), petroleum ether (PE), etc. Products of Group Chemical Reagent Co., Ltd. The ethanol used for extraction is industrial grade 95% ethanol, and the rest is analytically pure.

[0028] 2 Methods and results

[0029] Celery seed medicinal material 2 kg was extracted with 8 times the amount of 80% ethanol under reflux for 3 times, each time for 1.5 h. The extract was collected under reduced pressure at 55°C and concentrated to about 400 mL with ethanol, then 400 mL of 95% ethanol was added to the concentrated solution, heated to dissolve, 1 kg of silica gel (100-200 mesh) was added to the solution to mix the sample, and the column was loaded. Pack 1.5 kg of silica gel...

Embodiment 2

[0031] Example 2 Preparation of Apigenin A, Apigenin B and Neocnidolide II

[0032] 1 material

[0033] Celery seed; column chromatography filler: silica gel (100-200 mesh, 200-300 mesh), purchased from Zhifu Silica Gel Development and Experimental Factory in Yantai, Shandong; ethanol, ethyl acetate (EtOAc), petroleum ether (PE), etc. Products of Group Chemical Reagent Co., Ltd. The ethanol used for extraction is industrial grade 95% ethanol, and the rest is analytically pure.

[0034] 2 Methods and results

[0035] Celery seed medicinal material 2 kg was extracted with 8 times the amount of 80% ethanol under heat reflux for 3 times, each time for 1.5 hours. The extract was collected under reduced pressure at 55°C and concentrated to about 400 mL with ethanol, then 400 mL of 95% ethanol was added to the concentrated solution, heated to dissolve, 1 kg of silica gel (100-200 mesh) was added to the solution to mix the sample, and the column was loaded. Pack 1.5 kg of sili...

Embodiment 3

[0037] Embodiment 3 pharmaceutical composition of the present invention one

[0038] 30 parts of apigenin A, 19 parts of apigenin B, and 51 parts of neocnidolide are mixed directly.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating gout. The pharmaceutical composition consists of, by weight, pharmaceutical raw materials including butyl phthalide 25-35 parts, sedenenolide 15-25 parts and neocnidilide 40-55 parts. The invention further provides application of the pharmaceutical composition and phthalide compounds, namely the butyl phthalide, the sedenenolide and the neocnidilide in preparation of drugs for treating the gout. The pharmaceutical composition has the advantages that the pharmaceutical composition has the effect of promoting uric acid excretion and abirritation, three phthalide compounds, namely the butyl phthalide, the sedenenolide and the neocnidilide have certain xanthine oxidase inhibiting activity, and a novel source is provided for preparation of the drugs for inhibiting the xanthine oxidase activity or preventing and treating the gout.

Description

technical field [0001] The invention relates to the technical field of medicine, specifically, a pharmaceutical composition for treating gout and its application, and the preparation of phthalide compounds apigenin A, apigenin B and neocnidolide to inhibit the activity of xanthine oxidase Or the application in the treatment of gout medicine. Background technique [0002] Celery seed is a umbelliferous plant celery Apium graveolens The seeds of L., taking celery seed extract to relieve and treat joint pain has a history of 100 years in Australia. It is regarded as a traditional folk remedy. Modern nutrition has initially confirmed that celery seed oil contains beneficial nutrients for articular cartilage. . [0003] Scholars at home and abroad have reported that celery seed oil contains phthalide derivatives (Leonard F. Bjeldanes, In-Suk Kim, Phthalide Components of Celery Essential Oil. 1977, 42(13): 2333-2335); among them, apigenin A The content of neocnidolide and apig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P19/06
Inventor 陈海生高永良徐娜刘建国陈琰
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com